Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common painkiller boost brain development in preemies?

NCT ID NCT06064825

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 500 extremely preterm infants who received paracetamol or placebo in the TREOCAPA trial. Researchers will use a parent questionnaire to assess cognitive development at age 2. The goal is to see if early paracetamol use improves thinking and learning skills in these vulnerable children.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
paracetamol (acetaminophen)
What this could lead to
If successful, this could show that early paracetamol treatment helps prevent cognitive delays in extremely preterm infants.
What could go wrong
This is a follow-up study, not a new treatment trial. Results depend on parent reports, which may not be fully accurate, and the original trial may not show a clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population for the follow-up study of the TREOCAPA trial consists of all children included in phase III of the trial from centres participating in the follow-up study. The parents of children who survived to two years corrected age and meet the criteria for inclusion will be offered the opportunity to complete the questionnaire.

Ages

23 to 27 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * were included in the TREOCAPA phase III RCT in participating centres * are aged between 23.5 and 27.5 months corrected age during the study period Exclusion Criteria: * if the local investigator does not have up-to-date contact information allowing contact with parents * if the child's vital status cannot be ascertained * if the child is nearing the end of his life or experiencing a severe medical event as assessed by the local investigator * if the child has become subject to a legal protection measure preventing their ongoing participation in clinical research * if either parent or guardian opts out of participating * language barrier

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patency of the ductus arteriosus acetaminophen extreme prematurity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

patent ductus arteriosus Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patency of the ductus arteriosus acetaminophen extreme prematurity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU d'Angers

    RECRUITING

    Angers, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nantes

    RECRUITING

    Nantes, France

  • CHU de Strasbourg

    RECRUITING

    Strasbourg, France

  • CHU de Tours

    RECRUITING

    Tours, France

  • Cochin - APHP

    RECRUITING

    Paris, France

  • Hopital Robert Debré

    RECRUITING

    Paris, France

  • Hôpital Femme Mère Enfant

    RECRUITING

    Bron, France